Does Medicaid cover Wegovy?
Wegovy is FDA-approved specifically for chronic weight management, and whether Medicaid covers it depends entirely on whether your state has added the weight-loss indication to its preferred drug list — a growing but still inconsistent group of states.
What flips the answer
- Covered when
Your state's Medicaid preferred drug list specifically includes Wegovy for weight management, and you meet the BMI and comorbidity documentation prior authorization requires.
- Not covered when
Your state's Medicaid program excludes GLP-1 drugs for the weight-loss indication, even though it may cover the same drug class for diabetes.
- Not covered when
You haven't met prior authorization requirements, such as a documented weight-related condition or evidence of prior diet or lifestyle attempts.
- Not covered when
A prior authorization renewal is denied because demonstrated weight-loss progress didn't meet your state's reauthorization threshold.
Wegovy (semaglutide) is approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition — unlike Ozempic, which is approved for type 2 diabetes. Because Medicaid drug coverage is filtered through each state's preferred drug list, and weight-loss drugs have historically faced more scrutiny than diabetes drugs, Wegovy coverage is less consistent than coverage for GLP-1 diabetes medications.
States that do cover Wegovy typically require prior authorization tied to a minimum BMI, a documented weight-related comorbidity, and evidence that lifestyle or diet interventions have already been tried. Some states also require periodic reauthorization showing continued weight-loss progress to keep the prescription covered.
A number of states have specifically excluded GLP-1 drugs for the weight-loss indication from their preferred drug list, even while covering the same drug class for diabetes — so a Wegovy prescription can be denied in a state where Ozempic, for a diabetes diagnosis, would be approved. Because states have been adjusting these policies quickly as GLP-1 costs have grown, check your state's current preferred drug list rather than assuming last year's policy still applies.
Coverage for Wegovy specifically (as opposed to GLP-1 drugs for diabetes) varies widely by state and has been changing quickly. Some states cover it with BMI-based prior authorization criteria; others exclude the weight-loss indication from their preferred drug list entirely. Check your state Medicaid agency's current preferred drug list for the specific policy.
That's the general answer. Yours is written in your actual policy.
Drop in your policy or benefits document and get the answer for your exact coverage — with the clause it comes from. Nothing is stored.
Check my policy →